Organic Active Ingredients TRIZ Cases

Structural modifications of the triazole moiety reduce CYP3A4 inhibition while preserving anti-angiogenic efficacy for safer cancer combination therapy.

Extracellular matrix coating on PLGA nanoparticles enhances cellular uptake in lung tissue, reducing clearance by macrophages and mucociliary systems.

BET inhibitors treat age-related inflammatory diseases by blocking protein function, extending lifespan while minimizing cellular side effects.

Formula I compounds target B-Raf V600E mutants to resolve selectivity issues in melanoma therapy.

A chewable composition uses controlled gel strength to deliver accurate pharmaceutical doses in a palatable format.

A dietary composition combining psyllium husk, rice bran, and prebiotics to promote intestinal health.

Low-dose sympathicomimetic agonists activate adrenergic receptors to enhance thrombin generation and strengthen blood clots.

Merges mechanical filling with biological stimulation to extend filler duration while minimizing inflammatory reactions.

Segmented herbal extracts balance physiological parameters to eliminate side effects while improving energy, clarity, and sexual function.

Optimized cationic lipids with specific headgroups and chain lengths reduce cytotoxicity while maintaining high in-vivo delivery efficiency.

Multi-column adsorbent resin systems purify steviol glycosides through selective elution and crystallization.

A sequential interferon alpha regimen activates dormant cancer stem cells, enabling chemotherapy to eliminate resistant tumor populations.

Novel imidazopyridine compounds act as selective prostaglandin EP4 receptor antagonists to manage pain and inflammation.

A pharmaceutical composition uses hydrotropes to modify active agent lipophilicity, enabling direct penetration through mucosal membranes.

Esterified pectins bind Toll-like receptor 2 to regulate intestinal barrier function, avoiding side effects from cortisone derivatives.

Novel 1-benzyl-3-hydroxymethylindazole derivatives inhibit MCP-1 and CX3CR1 expression levels through targeted molecular modification.

Crystalline phosphate and D-tartrate salts convert viscous alpha-6-mPEG6-O-hydroxycodone into stable solid forms.

Selamectin overcomes emamectin resistance in sea lice populations while maintaining high selectivity and safety profiles for treated fish.

Oxadiazine compounds modulate gamma-secretase proteolytic parameters to lower Aβ42 levels while preserving Notch signaling and reducing side effects.

Substituted bicyclo piperazine amides inhibit IDO to enhance T-cell activation and antitumor responses.

Fluorinated LDHA inhibitors overcome rapid clearance by improving membrane permeability, sustaining target modulation in hypoxic tumors.

Merging AT1 antagonism and neprilysin inhibition into one molecule resolves the trade-off between blood pressure control efficacy and patient compliance.

Benzamide compounds target TrkA receptors to reduce pain and inflammation while minimizing off-target side effects.

EAAT3 inhibitor compounds modulate glutamate levels, addressing unmet needs in schizophrenia and bipolar disorder treatment.

A topical diindolylmethane composition delivers therapeutically effective amounts of the active ingredient directly to the skin.

Modifying lobaric acid structure with local quality principles to enhance bioavailability and overcome selectivity limits.

Segmented Formula IIIa compounds inhibit CDK9 to treat cancer while minimizing off-target toxicity.

Optimized crystal structures improve absorption and stability to reduce drug tolerance in Mer TK and FLT3 inhibitors.

DHP-I inhibitors mitigate neuroinflammation and preserve retinal ganglion cells by blocking dehydropeptidase-I enzymatic activity.

Pyrido[4,3-e]pyrrolo[1,2-a]pyrimidine compounds overcome drug resistance by inhibiting CK2 with high potency against cancer cell lines.

Oral reduced folate and silymarin composition prevents methotrexate-induced folate deficiency and liver toxicity.

TREX1 modulators inhibit exonuclease activity to resolve the contradiction between enhanced anti-tumor immunity and autoimmunity induction.

Buffering agents stabilize racecadotril in an aqueous suspension, preventing hydrolysis and enabling precise pediatric dosing.

Coupling protected aniline with carboxylic acid to form amide linkages, replacing Hofmann Rearrangement bottlenecks that limit commercial scale-up.

Phospholipid coatings on mesoporous silica nanoshuttles reduce non-specific protein adsorption and aggregation, enabling targeted drug delivery.

Intravenous nicotinamide adenine dinucleotide combined with amino acids restores brain chemical balance, reducing withdrawal severity.

Lenalidomide reduces cerebrospinal fluid inflammatory cytokines and leukocytes, resolving cognitive deficits caused by IRIS.

A fixed-dose pharmaceutical composition combines atovaquone and proguanil hydrochloride into a single unit.

Detects Uncharacterized Fungal Protein CIMG_09001 using specific antibodies to resolve early-stage diagnostic precision limits.

Formula I quinazolinones selectively inhibit PARP14, reducing IL-10 production and addressing inadequate current therapies.

MEK1 inhibitors block MAP2K1-driven signaling pathways to prevent arteriovenous malformation recurrence after initial embolization or resection.

Antibodies targeting D-dopachrome tautomerase resolve CD74 signaling gaps by treating ischemia-reperfusion injury.

Fermentation and chromatography concentrate anticancer saponins from Anemone raddeana and Lonicera extracts to inhibit cancer cells while sparing normal tissue.

Ambroxol topical formulation blocks Nav1.8 channels, reducing pain while preserving corneal sensation and lowering infection risk.

Functionalized calcium carbonate creates porous granules that disintegrate rapidly, resolving swallowing difficulties for vulnerable patient groups.